Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”)
22 Juni 2023 - 1:30PM
Avicanna Inc. (“
Avicanna” or the
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the commercialization of evidence-based, cannabinoid-based
products, is pleased to announce that it has entered into a
sponsorship agreement with the Canadian Consortium for the
Investigation of Cannabinoids (“
CCIC”) to sponsor
CICC in making available and providing access to the Canadian
Cannabis Syllabus (“
CCS”), continuing education
course accredited by the University of Calgary’s Office of
Continuing Medical Education and Professional Development,
available to the Canadian medical community.
“We are proud to be sponsoring CCIC who have
championed the advancement of evidence-based research and education
on the endocannabinoid system in Canada. In line with the launch of
MyMedi.ca and our commitment to advance medical cannabis access, we
believe that the CCS can be an effective tool to provide education
for healthcare providers and provide information to support the
adoption of medical cannabis by the medical community,” stated Dr.
Karolina Urban, EVP of Medical Affairs at Avicanna Inc.
“The CCIC is excited to develop this
relationship with Avicanna as it will help to ensure the
dissemination of accurate, scientifically valid and vetted
information regarding the biology of cannabis and how it impacts
the human body, potential therapeutic approaches that cannabis and
cannabinoid products could be leveraged for with respect to
specific disease states and putative health risks associated with
cannabis use and the development of cannabis use disorder,” stated
Dr. Matthew Hill, CCIC Executive Director
Through the sponsorship agreement the CCS will
be offered to healthcare providers interested in learning more
about medical cannabis as a part of their practice. The CCS
provides foundational knowledge and considerations for all
healthcare professionals interested in learning more about cannabis
and cannabinoid products in clinical practice. The course consists
of 9 modules including:
- Introduction to
the Endocannabinoid System
- Cannabis
Basics
- Long-term Health
Issues Associated with Cannabis
- Clinical Use of
Cannabis and Cannabinoids in Pain (3 modules)
- Clinical Use of
Cannabis in Non-pain Conditions
- Considerations
when Authorizing Cannabis
- Acute Adverse
Effects, Drug Interactions and Contraindications of Cannabis
- Cannabis Use
Disorder
- Cannabis Policy
in Canada
About the CCIC
The CCIC is a federally registered Canadian
not-for-profit corporation of basic and clinical researchers,
health care professionals and educators that promotes research and
evidence-based education concerning the endocannabinoid system, the
therapeutic applications of cannabinoids, the potential harms
associated with cannabis use and the health and societal impacts of
non-medical cannabis use. For more information, please visit
https://ccic.net.
About Avicanna Inc.
Avicanna is a Canadian commercial-stage
biopharmaceutical company focused on research, development, and
commercialization of evidence-based cannabinoid products for
medical and pharmaceutical market segments. Avicanna has an
established scientific platform and intellectual property portfolio
that has contributed to the international commercialization of over
thirty products across various market segments:
- Medical Cannabis &
Wellness Products (RHO Phyto™): The formulary offers
a diverse range of proprietary formulations including oral,
sublingual, topical, and transdermal deliveries with varying ratios
of cannabinoids and is supported with ongoing patient, and medical
community education. RHO Phyto has been established as a leading
medical brand in Canada and is currently available nationwide to
patients across several medical channels and continues to expand
into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive pipeline of patent-pending drug
candidates that are indication-specific and in various stages of
clinical development and commercialization. These cannabinoid-based
drug candidates look to address unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox™) is in the
drug registration stage in South America.
- MyMedi.ca Medical Cannabis
Care Portal: MyMedi.ca is Avicanna’s medical cannabis care
platform that is formed with the aim to better serve medical
cannabis patients’ needs and enhance the patient journey. MyMedi.ca
is expected to launch during August 2023 and will feature diverse
and scientifically curated products from leading Canadian licensed
producers in addition to pharmacist led patient support programs
and educational resources to facilitate the incorporation of
medical cannabis into health care regimens. MyMedi.ca also provides
specialty services to distinct patient groups such as veterans and
collaborating with public and private providers for adjudication
and reimbursement.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our
website, contact Ivana Maric by email at info@avicanna.com or
follow us on social media
on LinkedIn, Twitter, Facebook, or Instagram.
The Company posts updates through videos from the official
Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information
and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ea2b5dd1-34f6-478a-966c-ca51003b81df
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024